Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session – Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares WALTHAM, Mass.–(BUSINESS WIRE)–Jan. 24, 2023– Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH),...
Recent Comments